MA35623B1 - Composés de 1-arylcarbonyl-4-oxypipéridine utiles pour le traitement de maladies neurodégénératives - Google Patents

Composés de 1-arylcarbonyl-4-oxypipéridine utiles pour le traitement de maladies neurodégénératives

Info

Publication number
MA35623B1
MA35623B1 MA36973A MA36973A MA35623B1 MA 35623 B1 MA35623 B1 MA 35623B1 MA 36973 A MA36973 A MA 36973A MA 36973 A MA36973 A MA 36973A MA 35623 B1 MA35623 B1 MA 35623B1
Authority
MA
Morocco
Prior art keywords
treatment
oxypiperidine
arylcarbonyl
neurodegenerative diseases
compounds useful
Prior art date
Application number
MA36973A
Other languages
English (en)
Inventor
Tatsuki Koike
Masato Yoshikawa
Haruhi Ando
William John Farnaby
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47143241&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA35623(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of MA35623B1 publication Critical patent/MA35623B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Steroid Compounds (AREA)

Abstract

La présente invention concerne un composé utile comme agent pour la prophylaxie ou le traitement de maladie neurodégénérative et assimilée, ou un sel de celui-ci. La présente invention concerne un composé représenté par la formule (i) dans lequel chaque symbole est comme défini dans le mémoire descriptif, ou un sel de celui-ci.
MA36973A 2011-10-07 2014-05-04 Composés de 1-arylcarbonyl-4-oxypipéridine utiles pour le traitement de maladies neurodégénératives MA35623B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2011222741 2011-10-07
PCT/JP2012/076257 WO2013054822A1 (fr) 2011-10-07 2012-10-03 Composés de 1-arylcarbonyl-4-oxypipéridine utiles pour le traitement de maladies neurodégénératives

Publications (1)

Publication Number Publication Date
MA35623B1 true MA35623B1 (fr) 2014-11-01

Family

ID=47143241

Family Applications (1)

Application Number Title Priority Date Filing Date
MA36973A MA35623B1 (fr) 2011-10-07 2014-05-04 Composés de 1-arylcarbonyl-4-oxypipéridine utiles pour le traitement de maladies neurodégénératives

Country Status (43)

Country Link
US (11) US8648079B2 (fr)
EP (1) EP2763979B1 (fr)
JP (1) JP6117191B2 (fr)
KR (1) KR101967497B1 (fr)
CN (1) CN103842356B (fr)
AP (1) AP2014007606A0 (fr)
AR (1) AR088226A1 (fr)
AU (1) AU2012321815B2 (fr)
BR (2) BR122022001219B1 (fr)
CA (1) CA2851087C (fr)
CL (1) CL2014000806A1 (fr)
CO (1) CO6940432A2 (fr)
CR (1) CR20140151A (fr)
CY (1) CY1121549T1 (fr)
DK (1) DK2763979T3 (fr)
DO (1) DOP2014000064A (fr)
EA (1) EA025662B1 (fr)
EC (1) ECSP14013329A (fr)
ES (1) ES2716531T3 (fr)
GE (1) GEP201706608B (fr)
HR (1) HRP20190491T1 (fr)
HU (1) HUE043171T2 (fr)
IL (1) IL231678A (fr)
LT (1) LT2763979T (fr)
MA (1) MA35623B1 (fr)
ME (1) ME03372B (fr)
MX (1) MX360706B (fr)
MY (1) MY176126A (fr)
PE (1) PE20141120A1 (fr)
PH (1) PH12014500759A1 (fr)
PL (1) PL2763979T3 (fr)
PT (1) PT2763979T (fr)
RS (1) RS58470B1 (fr)
SG (1) SG2014010417A (fr)
SI (1) SI2763979T1 (fr)
SM (1) SMT201900173T1 (fr)
TN (1) TN2014000122A1 (fr)
TR (1) TR201902788T4 (fr)
TW (1) TWI582084B (fr)
UA (1) UA115133C2 (fr)
UY (1) UY34365A (fr)
WO (1) WO2013054822A1 (fr)
ZA (1) ZA201402424B (fr)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2851087C (fr) 2011-10-07 2019-09-24 Takeda Pharmaceutical Company Limited Composes de 1-arylcarbonyl-4-oxypiperidine utiles pour le traitement de maladies neurodegeneratives
WO2014061676A1 (fr) 2012-10-16 2014-04-24 武田薬品工業株式会社 Composé hétérocyclique
WO2014092100A1 (fr) 2012-12-11 2014-06-19 武田薬品工業株式会社 Composé hétérocyclique
RS67266B1 (sr) 2013-03-13 2025-10-31 Sage Therapeutics Inc Neuroaktivni steroidi i postupci za njihovu upotrebu
EP2982670B1 (fr) 2013-04-04 2018-11-07 Takeda Pharmaceutical Company Limited Composé hétérocyclique
US9598398B2 (en) 2013-04-04 2017-03-21 Takeda Pharmaceutical Company Limited Heterocyclic compound
JP6533799B2 (ja) * 2014-06-09 2019-06-19 武田薬品工業株式会社 放射標識された化合物
ES2970222T3 (es) 2014-06-18 2024-05-27 Sage Therapeutics Inc Oxiesteroles y procedimientos de uso de los mismos
CN104803922A (zh) * 2015-03-14 2015-07-29 长沙深橙生物科技有限公司 一种嘧啶衍生物的制备方法
MX390271B (es) 2015-07-06 2025-03-20 Sage Therapeutics Inc Oxiesteroles y metodos de uso de los mismos
FI3828194T3 (fi) 2015-07-06 2025-07-17 Sage Therapeutics Inc Oxysteroleita ja menetelmiä niiden käyttämiseksi
EP3363796B1 (fr) * 2015-10-16 2021-04-07 Takeda Pharmaceutical Company Limited Procédé de production de composé hétérocyclique
GB201604029D0 (en) 2016-03-09 2016-04-20 Ctxt Pty Ltd Compounds
US20190330259A1 (en) 2016-04-01 2019-10-31 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
WO2017193046A1 (fr) 2016-05-06 2017-11-09 Sage Therapeutics, Inc. Oxystérols et méthodes d'utilisation associées
WO2017195894A1 (fr) * 2016-05-13 2017-11-16 日産化学工業株式会社 Procédé de production d'un composé de type 2-acétylpyridine
JP7149266B2 (ja) 2016-09-30 2022-10-06 セージ セラピューティクス， インコーポレイテッド Ｃ７置換オキシステロールおよびｎｍｄａモジュレーターとしての方法
GB201617758D0 (en) 2016-10-20 2016-12-07 Almac Discovery Limited Pharmaceutical compounds
CA3073925A1 (fr) 2017-08-31 2019-03-07 Takeda Pharmaceutical Company Limited Traitement d'affections du snc
WO2020027344A1 (fr) 2018-08-03 2020-02-06 Takeda Pharmaceutical Company Limited Inhibiteurs de ch24h pour utilisation mdd
WO2020059894A1 (fr) 2018-09-20 2020-03-26 Takeda Pharmaceutical Company Limited Inhibiteurs de ch24h pour une utilisation contre la douleur
TWI855081B (zh) * 2019-05-24 2024-09-11 美商賽吉醫療公司 化合物、組合物及使用方法
US12029718B2 (en) 2021-11-09 2024-07-09 Cct Sciences, Llc Process for production of essentially pure delta-9-tetrahydrocannabinol
IL303170A (en) * 2020-11-25 2023-07-01 Sage Therapeutics Inc 4-fluoro-(4-(4-benzyl)piperidin-1-yl)(2-(pyrimidin-4-yl)pyridin-3-yl)methanone derivatives and similar compounds as cyp46a1 inhibitors for the treatment of neurodegenerative disorders
AU2022291395A1 (en) 2021-06-11 2024-01-04 Sage Therapeutics, Inc. Neuroactive steroid for the treatment of alzheimer's disease
KR20240121239A (ko) * 2021-12-17 2024-08-08 아티라 파마, 인코포레이티드 질환 치료를 위한 이환식 화합물의 용도
CN116444477B (zh) * 2023-04-04 2026-01-02 宁波九胜创新医药科技有限公司 一种溴代胡椒环羧酸的制备方法及其用途
WO2025019590A2 (fr) * 2023-07-18 2025-01-23 The General Hospital Corporation Chimères ciblant la protéolyse pour traiter la neurodégénérescence
WO2025126159A1 (fr) 2023-12-15 2025-06-19 Takeda Pharmaceutical Company Limited Procédé de traitement d'une maladie neurologique chez un utilisateur de drogue récréative
WO2025257799A1 (fr) 2024-06-14 2025-12-18 Takeda Pharmaceutical Company Limited Méthodes de traitement du syndrome de dravet

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5854204A (en) 1995-03-14 1998-12-29 Praecis Pharmaceuticals, Inc. Aβ peptides that modulate β-amyloid aggregation
CA2262453A1 (fr) 1996-08-27 1998-03-05 Praecis Pharmaceuticals Incorporated Modulateurs de l'agregation de peptides beta-amyloides, comprenant des d-aminoacides
CA2374346C (fr) 1999-06-28 2010-06-22 Jordan J. N. Tang Inhibiteurs de memapsine 2 et son utilisation
AR035016A1 (es) 1999-08-25 2004-04-14 Takeda Chemical Industries Ltd Composicion de azol promotor de produccion/secrecion de neurotrofina, compuesto prodroga del mismo, composicion farmaceutica que lo comprende y uso del mismo para preparar esta ultima.
ATE479429T1 (de) 2000-04-28 2010-09-15 Takeda Pharmaceutical Antagonisten des melanin-konzentrierenden hormons
CA2408913A1 (fr) 2000-05-16 2001-11-22 Takeda Chemical Industries, Ltd. Antagoniste de l'hormone de concentration de la melanine
AU2002248432A1 (en) 2001-02-14 2002-08-28 Sankyo Company, Limited Oxazole derivatives, their preparation and their use as cytokine inhibitors
CA2445568A1 (fr) 2001-04-27 2002-11-07 Vertex Pharmaceuticals Incorporated Derives triazole inhibiteurs des kinases et leurs utilisations
US20030195192A1 (en) 2002-04-05 2003-10-16 Fortuna Haviv Nicotinamides having antiangiogenic activity
US20040014744A1 (en) 2002-04-05 2004-01-22 Fortuna Haviv Substituted pyridines having antiangiogenic activity
AU2003288231A1 (en) 2002-12-13 2004-07-09 Bayer Healthcare Ag Cholesterol 24-hydroxylase (cyp46) as therapeutic target for the treatment of alzheimer's disease
DOP2005000039A (es) 2004-03-26 2005-10-31 Aventis Pharma Inc Hidrocloruro de [4-(5-aminometil-2-fluoro-fenil)- piperidin-1-il]-(4-bomo-3-metil-5-propoxi-tiofen-2-il)-metanona como un inhibidor de la triptasa de mastocitos
US20060167044A1 (en) 2004-12-20 2006-07-27 Arnaiz Damian O Piperidine derivatives and their use as anti-inflammatory agents
JPWO2006137465A1 (ja) 2005-06-24 2009-01-22 塩野義製薬株式会社 含窒素複素環誘導体
WO2007062999A2 (fr) 2005-11-30 2007-06-07 F. Hoffmann-La Roche Ag Derives de indole-2-yl amide substitues en 1,5
CA2634547C (fr) 2005-12-20 2016-10-11 Bristol-Myers Squibb Company Formulations de proteine stables
AU2007275301A1 (en) * 2006-07-20 2008-01-24 Amgen Inc. Substituted azole aromatic heterocycles as inhibitors of 11-beta-HSD-1
KR101476472B1 (ko) 2007-03-30 2015-01-05 암브룩스, 인코포레이티드 변형된 ｆｇｆ-21 폴리펩티드 및 그 용도
WO2008134547A1 (fr) 2007-04-25 2008-11-06 Xenon Pharmaceuticals Inc. Procédés de traitement de maladies ou d'affections associées aux canaux sodiques au moyen de composés d'hydroxycyclohexane et d'hydroxypipéridine
WO2008153722A1 (fr) 2007-05-22 2008-12-18 The Board Of Regents Of The University Of Texas System Régulation post-translationnelle d'activités catalytiques du cytochrome p450 46a1, et utilisations associées
WO2009117421A2 (fr) 2008-03-17 2009-09-24 Kalypsys, Inc. Modulateurs hétérocycliques de gpr119 pour le traitement d’une maladie
BRPI0916920A2 (pt) 2008-08-22 2015-11-24 Sanofi Aventis 4-(5-aminometil-2-fluoro-fenil)-piperidin-1-il]-[7-fluoro-1-(2-metóxi-etil)-4-trifluorometóxi-1h-indol-3-il]-metanona como inibidor de triptase de mastócito, seu uso e método de preparação, bem como forma cristalina
WO2010075376A2 (fr) 2008-12-23 2010-07-01 Abbott Laboratories Composés antiviraux
DE102009022896A1 (de) 2009-05-27 2010-12-02 Bayer Schering Pharma Aktiengesellschaft Substituierte Piperidine
DE102009022894A1 (de) 2009-05-27 2010-12-02 Bayer Schering Pharma Aktiengesellschaft Substituierte Piperidine
US9051296B2 (en) 2009-11-16 2015-06-09 Raqualia Pharma Inc. Aryl carboxamide derivatives as TTX-S blockers
JP5316468B2 (ja) 2010-04-09 2013-10-16 株式会社豊田自動織機 リアクトル構造
KR101764952B1 (ko) 2010-07-29 2017-08-03 리겔 파마슈티칼스, 인크. Ａｍｐｋ-활성화 헤테로시클릭 화합물 및 그의 사용 방법
US20140031547A1 (en) 2010-12-14 2014-01-30 Electrophoretics Limited CASEIN KINASE 1delta (CK 1delta) INHIBITORS AND THEIR USE IN THE TREATMENT OF NEURODE-GENERATIVE DISEASES SUCH AS TAUOPATHIES
CA2851087C (fr) * 2011-10-07 2019-09-24 Takeda Pharmaceutical Company Limited Composes de 1-arylcarbonyl-4-oxypiperidine utiles pour le traitement de maladies neurodegeneratives

Also Published As

Publication number Publication date
CR20140151A (es) 2014-05-26
RS58470B1 (sr) 2019-04-30
EA025662B1 (ru) 2017-01-30
EA201490747A1 (ru) 2014-08-29
KR101967497B1 (ko) 2019-04-09
US9440990B2 (en) 2016-09-13
US9586930B2 (en) 2017-03-07
CO6940432A2 (es) 2014-05-09
US20140088118A1 (en) 2014-03-27
US8871766B2 (en) 2014-10-28
US10550129B2 (en) 2020-02-04
PE20141120A1 (es) 2014-09-15
PT2763979T (pt) 2019-04-12
MY176126A (en) 2020-07-24
AU2012321815B2 (en) 2017-03-09
MX2014004253A (es) 2014-06-11
CA2851087A1 (fr) 2013-04-18
US9193709B2 (en) 2015-11-24
SI2763979T1 (sl) 2019-04-30
NZ623185A (en) 2016-01-29
US20190233436A1 (en) 2019-08-01
US8648079B2 (en) 2014-02-11
US11174272B2 (en) 2021-11-16
HRP20190491T1 (hr) 2019-05-03
WO2013054822A1 (fr) 2013-04-18
HUE043171T2 (hu) 2019-08-28
US20160326136A1 (en) 2016-11-10
UY34365A (es) 2013-05-31
US20140088146A1 (en) 2014-03-27
US10144743B2 (en) 2018-12-04
MX360706B (es) 2018-11-14
US20130090341A1 (en) 2013-04-11
BR112014007257A2 (pt) 2017-03-28
ZA201402424B (en) 2015-07-29
EP2763979A1 (fr) 2014-08-13
EP2763979B1 (fr) 2018-12-26
ME03372B (fr) 2020-01-20
US20200157117A1 (en) 2020-05-21
US20140228373A1 (en) 2014-08-14
CN103842356B (zh) 2017-03-15
US20210206781A1 (en) 2021-07-08
TN2014000122A1 (en) 2015-07-01
AP2014007606A0 (en) 2014-05-31
UA115133C2 (uk) 2017-09-25
US10717748B2 (en) 2020-07-21
ECSP14013329A (es) 2014-05-31
JP2014528904A (ja) 2014-10-30
TR201902788T4 (tr) 2019-03-21
PL2763979T3 (pl) 2019-06-28
CA2851087C (fr) 2019-09-24
TWI582084B (zh) 2017-05-11
JP6117191B2 (ja) 2017-04-19
DK2763979T3 (en) 2019-04-01
SG2014010417A (en) 2014-06-27
US20190071455A1 (en) 2019-03-07
AU2012321815A1 (en) 2014-04-24
US20170145031A1 (en) 2017-05-25
US10273245B2 (en) 2019-04-30
GEP201706608B (en) 2017-01-25
BR112014007257B1 (pt) 2023-04-25
ES2716531T3 (es) 2019-06-13
TW201329068A (zh) 2013-07-16
DOP2014000064A (es) 2014-07-15
US20150376205A1 (en) 2015-12-31
BR122022001219B1 (pt) 2023-03-14
PH12014500759A1 (en) 2014-05-12
CY1121549T1 (el) 2020-05-29
LT2763979T (lt) 2019-03-25
US8865717B2 (en) 2014-10-21
AR088226A1 (es) 2014-05-21
CN103842356A (zh) 2014-06-04
AU2012321815A8 (en) 2014-06-12
IL231678A0 (en) 2014-05-28
KR20140072902A (ko) 2014-06-13
CL2014000806A1 (es) 2014-09-05
SMT201900173T1 (it) 2019-05-10
IL231678A (en) 2017-03-30

Similar Documents

Publication Publication Date Title
EA201490747A1 (ru) 1-арилкарбонил-4-оксипиперидиновые соединения, полезные для лечения нейродегенеративных заболеваний
MA35861B1 (fr) Inhibiteur de la kinase régulant les signaux de l'apoptose
EA201390794A1 (ru) Бициклическое соединение
MA38390A1 (fr) Composés tétrahydropyrrolothiazines
MA46337A (fr) Composé de pyridine
EA201400735A1 (ru) Производные альфа-амино бороновой кислоты, селективные ингибиторы иммунопротеасомы
MD4659B1 (ro) Polimorf al inhibitorilor SYK
EA201690153A1 (ru) Замещенные бензофуранильные и бензоксазолильные соединения и их применения
EA201690094A1 (ru) Ингибиторы syk
EA201490272A1 (ru) Новые 4-пиперидинильные соединения для применения в качестве ингибиторов танкиразы
MA35351B1 (fr) Nouveau dérivé 1,2,3,4- tétrahydroquinoléine utile pour le traitement du diabète.
EA201891553A1 (ru) Ингибиторы syk
EA201201030A1 (ru) 5-алкинилпиримидины
MX343561B (es) Compuestos de imidazolpiridazina.
EA201490493A1 (ru) Пирано[3,2-d][1,3]тиазол в качестве ингибиторов гликозидазы
MA34965B1 (fr) Procédé de production de dérivé de dihydrobenzofurane optiquement actif
MA39688A (fr) Composés hétéroaryle pour le traitement de maladies ophtalmiques
EA201400976A1 (ru) Бензодиоксаны в комбинации с другими активными средствами для ингибирования продуцирования лейкотриена
EA201690972A1 (ru) Конденсированные гетероциклические соединения в качестве модуляторов ионных каналов
EA201992306A1 (ru) Ингибиторы ip6k
SA523451905B1 (ar) Cdk2 مركبات بيريميدينيل-بيرازول بها استبدال كمثبطات
MX2015013936A (es) Compuestos de pirimidina condensada sustituida.
MA34556B1 (fr) Triazoles fusionnés pour le traitement ou la prophylaxie du trouble cognitif léger
MA38410B1 (fr) Composés d'azétidinyloxyphénylpyrrolidine
EA201300092A1 (ru) Замещенные производные оксадиазола